---
schema_version: "secwatch.filing_event.v1"
accession: "0001295947-23-000032"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:30:57.789894+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prestige Consumer Healthcare Q2 rev $286.3M, EPS $1.07, leverage down to 3.0x

## Summary
- Q2 FY2024 revenue $286.3M, slightly below prior-year record of $289.3M but ahead of internal outlook.
- Diluted EPS $1.07 vs $1.02 YoY, up 5.4%; net income $53.6M vs $51.0M.
- North American OTC revenue fell 3% to $244.4M; International OTC rose ~12.6% to $41.9M.
- Non-GAAP free cash flow $59.5M, up from $55.2M; covenant leverage ratio improved to 3.0x.
- FY2024 outlook reaffirmed: rev $1,135-1,140M, diluted EPS $4.27-4.32, FCF $240M+.

## SEC filing metadata
- accession: 0001295947-23-000032
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000032/0001295947-23-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000032/pbh-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001295947-23-000032
- JSON: https://secwatch.observer/filing/0001295947-23-000032.json
- Plain text: https://secwatch.observer/filing/0001295947-23-000032.txt

## Key facts
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $286.3 million, net income $53.6 million, EPS $1.07. Guidance reaffirmed.
  - Period: the fiscal quarter ended September 30, 2023
  - Revenue: $286.3 million
  - Net income: $53.6 million
  - EPS: $1.07
  - Guidance: reaffirmed
  - Result: reported results
  source text: Reported revenues in the second quarter of fiscal 2024 of $286.3 million compared to a record $289.3 million in the second quarter of fiscal 2023. Revenues decreased 0.7% versus the prior year second quarter excluding the impact of foreign currency. The revenue performance for the quarter was led by Cough & Cold and Ear & Eye Care category performances in North America and strong International OTC segment growth versus the prior year comparable period, offset by declines in certain other categories and the planned strategic exit of private label revenues. Reported net income for the second quarter of fiscal 2024 totaled $53.6 million, compared to the prior year second quarter’s net income of $51.0 million. Diluted earnings per share of $1.07 for the second quarter of fiscal 2024 increased 5.4% versus $1.02 in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000032/0001295947-23-000032-index.htm
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the six months ended September 30, 2023 results: revenue $565.6 million, net income $106.8 million, EPS $2.13. Guidance reaffirmed.
  - Period: the six months ended September 30, 2023
  - Revenue: $565.6 million
  - Net income: $106.8 million
  - EPS: $2.13
  - Guidance: reaffirmed
  - Result: reported results
  source text: Reported revenues for the first six months of fiscal 2024 totaled $565.6 million and compared to revenues of $566.3 million for the first six months of fiscal 2023. Revenues increased 0.5% versus the prior year six-month period, excluding the impact of foreign currency. The revenue growth for the first six months was driven by International OTC segment performance and strong Dermatological category sales in North America, offset by lower Women’s Health category sales and the strategic exit of private label revenues. Reported net income for the first six months of fiscal 2024 totaled $106.8 million versus the prior year comparable period net income of $106.3 million. Diluted earnings per share were $2.13 for the first six months of fiscal 2024 increased compared to diluted earnings per share of $2.11 in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594723000032/0001295947-23-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.